In:
Cancer Medicine, Wiley, Vol. 5, No. 8 ( 2016-08), p. 1791-1801
Abstract:
The MDM 2 protein plays an important role in the regulation of cell proliferation and apoptosis via ubiquitination and proteasome‐mediated degradation of p53. The genetic polymorphism rs2279744 (c.309T 〉 G) of the MDM 2 gene is reportedly associated with susceptibility and/or prognosis in various cancers. In this study, we investigated the risk factors for worse survival in patients with lung adenocarcinoma ( AC ). We examined the association between c.309T 〉 G and the prognosis of lung cancer by retrospectively reviewing 453 lung cancer patients. We studied both, clinicopathological and genetic characteristics, including the c.309T 〉 G, p53 Arg72Pro, EGFR , KRAS , and p53 mutations. Associations between these factors and survival outcome were analyzed using Cox proportional hazards models. The frequencies of MDM 2 polymorphisms were T/T, 20.8%; T/G, 48.6%, and G/G, 30.7%. The overall survival ( OS ) of AC patients with pathological stage I disease and the MDM 2 T/T genotype was significantly shorter than that of those with the T/G or G/G genotypes ( P = 0.02). Multivariate analysis revealed that the MDM 2 T/T genotype was an independent, significant prognostic factor (hazard ratio [ HR ] = 2.23; 95% confidence interval [ CI ]: 1.07–4.65; P = 0.03). The MDM 2 T/T genotype was predictive of poorer survival in a Japanese population. Genotyping for this polymorphism might predict the clinical outcomes of stage I AC patients.
Type of Medium:
Online Resource
ISSN:
2045-7634
,
2045-7634
DOI:
10.1002/cam4.2016.5.issue-8
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
2659751-2
Permalink